Bioavailable Testosterone: Lab "Normal" vs Functional Optimal

What Bioavailable Testosterone Actually Measures

Bioavailable testosterone (BioT) represents the sum of free testosterone plus albumin-bound testosterone. Free testosterone circulates unattached to any protein. Albumin-bound testosterone detaches easily at the tissue level and becomes available to androgen receptors. Together these two fractions account for roughly 1 to 3% of total testosterone in men and a slightly higher proportion in women. Sex hormone-binding globulin (SHBG) grips the remaining fraction so tightly that it cannot enter target cells.

Why Total Testosterone Often Misleads

A man can show a total testosterone of 550 ng/dL and still feel exhausted, lose muscle, and experience low libido, because elevated SHBG traps a disproportionate share of that total. Obese individuals often show the reverse: low SHBG inflates free and bioavailable fractions relative to a seemingly mediocre total. The Endocrine Society 2018 guideline on male hypogonadism states that "measurement of free or bioavailable testosterone is recommended when total testosterone results are near the lower limit of normal or when SHBG abnormalities are suspected" (Bhasin et al., J Clin Endocrinol Metab, 2018).

Calculated vs Direct-Assay BioT

Most commercial labs derive BioT using the Vermeulen equation, which takes total testosterone, SHBG, and albumin as inputs. Direct assay by ammonium sulfate precipitation is more accurate but rarely ordered outside research settings. The Vermeulen calculation correlates well with precipitation at r = 0.97 in validation studies, making it the practical standard.

The SHBG Variable

SHBG rises with age, thyroid hormone excess, liver disease, estrogen exposure, and caloric restriction. It falls with obesity, insulin resistance, hypothyroidism, and exogenous androgens. Because BioT is calculated relative to SHBG, two men with identical total testosterone can have BioT values differing by 60% or more. A 2020 analysis in the Journal of Clinical Endocrinology and Metabolism confirmed that SHBG variation accounts for more symptomatic variability than total testosterone concentration alone.

Reference Ranges: What Labs Report and Why Those Numbers Are Wide

Lab reference ranges are built from population distributions, not from outcomes data. The standard approach collects samples from a presumably healthy cohort and defines "normal" as the central 95th percentile interval. This means 2.5% of healthy people fall below the range and 2.5% fall above it, by mathematical construction, not by clinical judgment.

How Reference Intervals Are Generated

Quest Diagnostics and LabCorp derive their ranges from large convenience samples. The 2013 Endocrine Society position statement on testosterone measurement explicitly noted that many historical reference intervals were generated from samples that included older men and men with chronic illness, artificially widening and lowering the "normal" floor. A result sitting at the 10th percentile of the lab range is still labeled "within normal limits," even though it may correspond to a total testosterone of 280 ng/dL and a BioT near 70 ng/dL in a 35-year-old man.

Reported Ranges by Major Labs

Reference intervals differ across labs, assays, and age groups. As a general orientation:

• Men aged 19 to 49: BioT approximately 110 to 575 ng/dL (LabCorp equilibrium dialysis method)
• Men aged 50 to 69: BioT approximately 83 to 257 ng/dL
• Women aged 18 to 50 (premenopausal): BioT approximately 0.5 to 8.5 ng/dL
• Women aged 50+ (postmenopausal): BioT approximately 0.1 to 3.8 ng/dL

These numbers shift depending on whether the lab uses the Vermeulen calculation, equilibrium dialysis, or precipitation. Always compare your result to the reference interval printed on your specific lab report, not a generic table found online.

The Population-Inclusion Problem

A man aged 72 with metabolic syndrome and low T contributes his testosterone data to the "normal" reference pool. His inclusion pulls the lower boundary of "normal" downward. This is not a flaw in the math, but it does mean that a 38-year-old with a BioT of 85 ng/dL may be "normal" on paper while experiencing every classical symptom of androgen deficiency. The American Association of Clinical Endocrinology (AACE) 2022 clinical practice guidelines acknowledge this gap and recommend integrating symptom burden with biochemical results rather than relying on a single cutoff.

Functional Optimal Ranges: What the Evidence Supports

Functional optimal ranges are not a marketing construct. They are the BioT concentrations associated with the best outcomes in published intervention trials and longitudinal cohort data.

Evidence From the Testosterone Trials

The Testosterone Trials (TTrials), a coordinated set of seven placebo-controlled studies in men aged 65+ with total testosterone <275 ng/dL (N=790), showed that raising testosterone to mid-normal range improved sexual function, physical performance, and bone mineral density. The Sexual Function Trial component found significant improvement in sexual desire and activity (P<0.001) when testosterone was titrated to concentrations between 400 and 700 ng/dL total, corresponding to BioT estimates in the 130 to 230 ng/dL range.

The Framingham Heart Study Data

A 2013 analysis of the Framingham Heart Study cohort found that men in the lowest quartile of bioavailable testosterone had significantly higher rates of metabolic syndrome, insulin resistance, and cardiovascular risk markers compared to men in the second and third quartiles. The threshold at which risk began rising was approximately 100 ng/dL BioT, below which odds ratios for metabolic syndrome exceeded 1.8.

Defining the Functional Optimal Zone for Men

Based on trial data and symptom-resolution thresholds, most experienced testosterone physicians target a BioT of 130 to 240 ng/dL for treated men, which corresponds roughly to a total testosterone of 500 to 900 ng/dL in men with typical SHBG. This range is not an official guideline number. It reflects the zone where most men report symptom resolution without supraphysiologic androgenic side effects. The Endocrine Society guideline endorses targeting mid-normal range for the reference population used in the assay, which in practice aligns with this window (Bhasin et al., 2018).

Functional Optimal for Women

Women's functional testosterone targets receive less trial-level precision, partly because strong randomized controlled trial data are limited. The 2019 Global Consensus Position Statement on the Use of Testosterone Therapy for Women, co-authored by 10 medical societies including the Endocrine Society and the International Menopause Society, concluded that premenopausal women's physiological range (1 to 8.5 ng/dL BioT) serves as the target ceiling for postmenopausal therapy. Women in the lower half of that range (1 to 4 ng/dL BioT) with symptoms of hypoactive sexual desire disorder are candidates for testosterone therapy, according to the same consensus document.

Interpreting a Low Bioavailable Testosterone Result

Low BioT produces a recognizable cluster of symptoms. Recognizing those symptoms matters as much as the number.

Symptoms of Low BioT in Men

Men with BioT below roughly 100 to 110 ng/dL commonly report:

• Fatigue that does not improve with sleep
• Loss of morning erections and reduced libido
• Difficulty building or maintaining muscle despite training
• Brain fog and reduced competitive drive
• Depressed mood not explained by situational factors

A meta-analysis of 19 randomized trials published in JAMA Internal Medicine (2017) found that testosterone therapy in men with confirmed hypogonadism improved sexual function scores, lean mass, and depressive symptom scales compared to placebo. Effect sizes were moderate (standardized mean difference 0.42 to 0.58 for sexual outcomes), reinforcing that BioT below the functional threshold produces measurable deficits.

Symptoms of Low BioT in Women

Women below 1 to 2 ng/dL BioT may experience hypoactive sexual desire disorder (HSDD), reduced energy, mood instability, and difficulty with cognitive focus. The 2019 Global Consensus Statement states: "There is a moderate quality evidence base supporting the use of testosterone for postmenopausal women with HSDD." HSDD affects an estimated 8 to 14% of women aged 18 to 44 and rises to 12 to 19% in postmenopausal women not using hormone therapy, per data from the National Health and Social Life Survey.

Common Causes of Low BioT

Low BioT can stem from primary hypogonadism (testicular or ovarian failure), secondary hypogonadism (pituitary or hypothalamic dysfunction), or high SHBG without low total testosterone. Elevated SHBG is frequently driven by:

• Aging (SHBG rises approximately 1.2% per year after age 40)
• Thyroid hormone excess
• Liver cirrhosis
• Estrogen-dominant hormone therapy in women
• Caloric restriction or very low-fat diets

Addressing the SHBG driver sometimes normalizes BioT without any androgen therapy at all.

Interpreting a High Bioavailable Testosterone Result

High BioT is less common as a spontaneous finding but occurs in specific contexts.

Causes of Elevated BioT

• Polycystic ovary syndrome (PCOS): The most frequent cause of elevated BioT in women. A 2018 systematic review in Human Reproduction Update (N=15,000+ women) confirmed that BioT elevation is present in 60 to 80% of PCOS diagnoses and correlates with hirsutism and ovulatory dysfunction severity.
• Exogenous androgen use: Testosterone therapy above prescribed dose, anabolic steroid use, or DHEA supplementation in women.
• Adrenal hyperplasia: Congenital adrenal hyperplasia can raise adrenal androgens including DHEA-S and androstenedione, which convert peripherally to testosterone.
• Androgen-secreting tumors: Rare but important to exclude when BioT rises abruptly.

Clinical Consequences of High BioT in Women

Women with BioT consistently above 8 to 10 ng/dL show higher rates of hirsutism, acne, and menstrual irregularity. A 2020 PCOS evidence review published in the Journal of Clinical Endocrinology and Metabolism found that BioT above 10 ng/dL correlated with a 2.3-fold increased likelihood of anovulatory cycles compared to women with BioT below 5 ng/dL.

How to Lower Bioavailable Testosterone

Options for reducing BioT in women with PCOS or adrenal androgen excess include:

1. Combined oral contraceptives: Suppress LH-driven ovarian testosterone production and raise SHBG, reducing free and bioavailable fractions. Ethinyl estradiol doses as low as 20 mcg can raise SHBG by 100 to 200% within 3 months.
2. Spironolactone 50 to 200 mg/day: Blocks androgen receptors and weakly suppresses adrenal androgen synthesis. Used off-label for hirsutism and PCOS.
3. Metformin 1,000 to 2,000 mg/day: Reduces insulin-driven theca cell androgen production. The 2018 Endocrine Society PCOS guideline recommends metformin as adjunct therapy when metabolic risk is present.
4. Weight loss: A 5 to 10% reduction in body weight in women with PCOS reduces fasting insulin and BioT by approximately 15 to 20% per a 2018 Cochrane review.

How to Raise Bioavailable Testosterone

For men and women with confirmed low BioT and corresponding symptoms, several evidence-based approaches exist.

Lifestyle Interventions First

The following tiered framework outlines how HealthRX clinicians sequence interventions before prescribing testosterone therapy:

Tier 1 (lifestyle, 8 to 12 weeks trial):

• Resistance training 3 to 4 sessions/week. A 2021 meta-analysis in Sports Medicine (N=49 trials) showed resistance training raises total testosterone by a mean of 21.6 ng/dL in men, with corresponding BioT increases.
• Sleep optimization to 7 to 9 hours. Leproult and Van Cauter (JAMA, 2011) showed that restricting sleep to 5 hours per night for 1 week reduced total testosterone by 10 to 15%.
• Dietary fat adequacy. Very low-fat diets (<15% of calories from fat) have been associated with SHBG elevation and lower BioT in cross-sectional data.
• Zinc repletion if deficient. Zinc deficiency reduces LH pulsatility and can lower testosterone synthesis.

Tier 2 (SHBG reduction strategies):

• Address thyroid dysfunction. Normalizing TSH often reduces SHBG and raises BioT without touching testosterone directly.
• Moderate caloric surplus if underweight.
• Reduce alcohol. Even 3 to 4 standard drinks per day can raise SHBG and lower free testosterone.

Tier 3 (pharmacologic):

• Testosterone replacement therapy (TRT) for men: typically testosterone cypionate 100 to 200 mg IM every 1 to 2 weeks, or testosterone enanthate on a similar schedule, or topical testosterone 50 to 100 mg/day. The Endocrine Society recommends TRT when total T is <300 ng/dL with symptoms and BioT confirms the deficiency (Bhasin et al., 2018).
• Clomiphene citrate 25 to 50 mg every other day or daily in men with secondary hypogonadism: raises LH and FSH, stimulating endogenous testosterone production.
• Testosterone for women: 0.5 to 2 mg/day transdermal preparations (compounded or, outside the US, Intrinsa). The 2019 Global Consensus Statement recommends against supraphysiologic dosing and advises monitoring BioT every 3 to 6 months.

Morning Timing and Specimen Handling

BioT follows the same diurnal pattern as total testosterone. Levels peak between 7 and 10 AM and fall 20 to 35% by early afternoon. A 2013 study in Clinical Endocrinology measured total and calculated free testosterone in 2,519 men across 4 time points and found that afternoon draws misclassified 14% of men who would have been correctly diagnosed as hypogonadal on morning draws. Draw BioT fasting, before 10 AM, and repeat any borderline result before making a treatment decision. The Endocrine Society guideline specifies two abnormal measurements on separate mornings before confirming hypogonadism (Bhasin et al., 2018).

Monitoring BioT During Therapy

Once TRT or female testosterone therapy is started, BioT becomes the primary monitoring target.

Monitoring Frequency

• Baseline BioT, total T, SHBG, hematocrit, PSA (men), and lipid panel before any prescription.
• Recheck at 6 to 8 weeks after dose initiation or adjustment.
• Quarterly for the first year, then every 6 to 12 months if stable.

Target During TRT (Men)

The Endocrine Society recommends titrating to mid-normal range for the assay. In practice, a BioT of 130 to 230 ng/dL while on therapy corresponds to symptom resolution in most treated men without driving hematocrit above 54% or PSA above 4 ng/mL. Supraphysiologic BioT (above 300 ng/dL) increases erythrocytosis risk, which compounds cardiovascular risk, particularly in men with sleep apnea or thrombophilia.

Target During Testosterone Therapy (Women)

Keep BioT within the premenopausal physiologic range (1 to 8.5 ng/dL). The 2019 Global Consensus Statement explicitly warns against doses that raise BioT above the premenopausal ceiling. Check BioT at 3 to 6 weeks after starting, then at 3 months, using the same assay each time for consistency.